Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › motavizumab

motavizumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of motavizumab

5 trials tracked of motavizumab: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 191 citations.

5Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 2 Phase 1 1 Other / NA 1
  1. Phase 3 MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States Completed · 191 cited
  2. Phase 2 A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease Completed
  3. Phase 2 Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season Completed
  4. Phase 1 Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection Completed
  5. N/A A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Monoclonal antibodies reduce RSV-related hospitalizations in premature infants with nirsevimab showing highest SUCRA values
Pediatrics Meta-analysis
Monoclonal antibodies reduce RSV-related hospitalizations in premature infants with nirsevimab showing highest SUCRA values Monoclonal antibodies reduce hospital stays for babies with RSV
This systematic review and network meta-analysis evaluated monoclonal antibodies for respiratory syncytial virus disease in premature infant…
Three different monoclonal antibodies all reduced the risk of hospitalization for premature infants with RSV infections, with one showing th…
Frontiers Jul 3, 2026